Janus Henderson Group PLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Janus Henderson Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.63 - $21.74 $105 - $130	6 Added 0.05%	12,359 $243,000
Q4 2023 Feb 14, 2024	SELL	$14.37 - $19.07 $373 - $495	-26 Reduced 0.21%	12,353 $216,000
Q3 2023 Nov 14, 2023	BUY	$13.62 - $20.2 $40 - $60	3 Added 0.02%	12,379 $215,000
Q1 2023 May 15, 2023	BUY	$10.7 - $15.79 $132,423 - $195,417	12,376 New	12,376 $133,000
Q3 2021 Nov 16, 2021	SELL	$11.39 - $16.23 $12.5 Million - $17.8 Million	-1,096,252 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$13.22 - $19.09 $405,193 - $585,108	-30,650 Reduced 2.72%	1,096,252 $15.3 Million
Q1 2021 May 17, 2021	SELL	$16.68 - $23.97 $100,847 - $144,922	-6,046 Reduced 0.53%	1,126,902 $20.9 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $21.15 $217,367 - $310,630	14,687 Added 1.31%	1,132,948 $20 Million
Q3 2020 Nov 16, 2020	BUY	$15.21 - $25.53 $17 Million - $28.5 Million	1,118,261 New	1,118,261 $17.1 Million

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.